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Background: Cancer cell differentiation is an important characteristic of malignant tumor and has a great impact
on prognosis and therapeutic decision for patients. The N-myc downstream regulated gene 1 (NDRG1), a putative
tumor suppression gene, is involved in the regulation of human cell differentiation and metastasis in various
cancers. Changes in the status of methylation of the NDRG1 gene have not been studied in detail in human breast
cancer.
Results: The MDA-MB-231 breast tumor cell line could express NDRG1. However, it was only expressed after
treatment with 5-Aza-2'-deoxycytidine (AZA) in T47D cell line, which revealed that NDRG1 expression could
modulated by DNA methylation. Therefore, the fragment surrounding the transcript start site of NDRG1 gene
promoter was cloned after sodium bisulfite DNA treatment. A high density (66%) of methylation for human NDRG1
gene promoter was detected in T47D; however, there was only 16% of methylated CpG dinucleotides in the
NDRG1 gene promoter in MDA-MB-231. DNA methylation in the NDRG1 promoter was detected in 31.1% of
primary breast cancer samples. Furthermore, the NDRG1 promoter methylation correlated with the Tumor Node
Metastasis (TNM) at stage III/IV, metastasis, lymph invasion, moderate and poor histological grade in the breast
cancer patients.
Conclusion: These findings suggest that the DNA methylation status of NDRG1 gene may play an important role in
the pathogenesis and/or development of breast cancer, and the expression could be regulated by aberrant DNA
methylation.
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Breast cancer is one of the most common malignancies
in women and is considered a genetic disease [1]. Like
other cancers, it is involved in tumor occurrence and
development because it influences oncogene and tumor
suppressor gene expression as well as genomic stability.
N-myc downstream regulated gene 1 (NDRG1), which
has been mapped to the human chromosome 8q24.2,
has a cDNA length of 1182 bp and encodes a cytoplasmic
43 kD protein. Previous studies have shown that NDRG1
expression is down-regulated in various cancer tissues,* Correspondence: qdqyhl@126.com
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reproduction in any medium, provided the orsuch as colon, prostate, and breast cancer tissues [2-4].
Accordingly, Kurdistani et al. [5] also reported that
NDRG1 was downregulated in various cancer cell lines,
and the growth of tumor cells is inhibited when the
tumor cell line is transfected with NDRG1 cDNA. Mean-
while, low expression of NDRG1 is liked to result in a
poor clinical outcome in breast cancer [3]. Together,
these results suggest that NDRG1 is a tumor suppressor
gene in various human cancers and the mechanism of
NDRG1 gene expression loss needs to be investigated.
One way in which cancer cells depress tumor suppressor
gene expression is through epigenetic alterations, which
include DNA hypermethylation of the promoter CpG
islands [6,7]. Genes with an abnormal methylation status,
silenced by hypermethylation or activated by demethyla-
tion, are important for the development [8], progression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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downstream regulated gene (NDRG1) was described as
a potential tumor suppressor gene in various human
cancers, and could be associated with tumor aggressiveness
and metastasis [11-13]. Recent research found that NDRG1
is upregulated in gastric, colon and pancreatic cancer
cells through demethylation of the CpG loci in the
promoter region [14,15], suggesting that the epigenetic
regulation mechanism plays an important role in acti-
vating NDRG1 expression during cancer progression
and gives cancer cells a changeable trait. Interestingly,
NDRG1 was revealed in the existence of CpG islands
through the computational analysis of its promoter region
by Meth-Primer (http://www.urogene.org/methprimer/in-
dex1.html). However, in studies of breast cancer tissues,
the methylation status of NDRG1 has not been reported.
In the present study, we first examined the rela-
tionship between the methylation status of the NDRG1
gene promoter and its steady-state expression in breast
tumors, corresponding normal tissues and two breast
cancer cell lines. Using bisulfite sequencing, as well as
nested-methylation-specific PCR (nested-MSP), we further
analyzed the different NDRG1 methylation status in these
two breast cancer cell lines. The methylation status in
the breast tumor samples was also detected and the as-
sociation with the clinicopathological data was analyzed
to further explore the relationship between the methy-




All tissue samples were obtained from the surgical speci-
mens of patients who underwent mastectomy at the affili-
ated hospital of Qingdao university. All patients provided
informed consent, and all procedures were approved by
the hospital’s ethics board. The collected tissue samples
were taken form unrelated Chinese women, aged 26 to 86
years (mean 52.3 ± 10.6), with sporadic breast cancer;
there were 389 samples (302 paraffin embedding tissues
and 87 fresh frozen tissues) containing >50% tumor area.
Meanwhile, corresponding fresh-frozen normal tissues
from the same patient, located at least 5 cm away from
the tumor site, were also collected. These tissues were
collected after reconfirmation by a senior pathologist from
the Affiliated Hospital of Qingdao University. The histo-
logical grades of each tumor was determined according to
the modified Bloom-Richardson criteria, and the Tumor
Node Metastasis (TNM) stage was determined with the
official classification methods [16].
Cell culture and treatment with 5-Aza-2′-deoxycytidine (AZA)
Human breast cancer cell lines MDA-MB-231 and
T47D were maintained in RPMI 1640 (GIBCO BRL,Grand Island, NY, USA) and supplemented with 10%
fetal bovine serum (Hyclone, Logan, UT) at 37°C in
the humidified atmosphere with 5% CO2. After serum
starvation for 24 hours, two breast cancer cell lines
were seeded at 105 cells in four-well plates, allowed to
attach for 24 hours and treated with 0, 2.5, 5 and 10
μM of the de-methylating agent, AZA.
Reverse transcription (RT) PCR assay
Total RNA was extracted from breast cell lines and
cDNA was prepared by RT-PCR kit (promega) according
to the instructions. The primer used was NDRG1: 5′-
ACTCCTCTGGAAAGACTTGTGC-3′ and 5′-AGTTG
GGAGGAGGAAGTAGTCC3′ (D87953), 175 bp. GAPDH
was used as a internal control: 5′-CAAGGTCATCCATG
ACAACTTTG-3′ and 5′-GTCCACCACCCTGTTGCTG
TAG-3′, 491 bp. The PCR products were subjected to
gel electrophoresis in 2% agarose gels.
Protein extraction and western blotting
Total protein from MDA-MB-231 and T47D cell lines
were extracted with standard method. The protein con-
centration was routinely analyzed by 12% SDS-PAGE.
Protein was transferred to nitrocellulose membrane, which
was blocked with 5% non-fat dry milk and incubated
with rabbit anti-NDRG1 primary antibody (Zymed, San
Francisco, CA) overnight at 4°C. The secondary horse-
radish peroxidase-conjugated anti-rabbit antibody was
visualized with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, US). Equal protein loading
was confirmed through β-actin.
Sodium bisulfite sequencing analysis and nested-MSP
The genomic tumor DNA was isolated from the MDA-
MB-231 and T47D breast cancer cell lines or tissue
samples using phenol-chloroform. The DNA was then
converted from unmethylated cytosines into uracils by
bisulfite with EZ DNA Methylation-Gold Kit (Zymo
Research, Orange, CA, USA) according to the manufac-
turer’s instructions. Previous studies have revealed that
the region surrounding the transcription start sites (+1)
of genes may regulate their expression [17]. We elected
the region from −379 to +86 as target fragment. The
primers were analyzed by Methyl Primer Express v1.0
software (http://www.appliedbiosystems.com/absite/us/
en/home/support/software-community/free-ab-software.
html) using GenBank NM_006096 (NDRG1) as the ref-
erence sequence (outside primer: sense, 5′ -AGAAATT
TTGAGGTAGAGATGGG-3′, antisense, 5′-ACTTCAAC
ACCAACTAAAAACCA-3′, 465 bp; methylated primer:
sense, 5′-GGGTTTCGATGTTTTTTTCGGC-3′, antisense,
5′-GCAATCCCAACACGC AACCGAAA-3′, 170 bp; un-
methylated primer: sense, 5′-GGGTTTTGATGTTTTTTT
TGGT-3′ ; antisense, 5′ -ACAATCCCAACACACAACCA
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in 25 uL reactions using perfectshot Taq (Takara), 10 pmol
of outsider primer and 30 ng modified DNA and the
following cycle parameters: 95°C for 5 min, then 35 cycles
of 95°C for 30 s, 52°C for 40 s, 72°C for 40 s, followed by a
final extension of 72°C for 5 min. Aliquots of 1 uL PCR
products were subjected to second round amplification
using methylated and unmethylated primer, respectively.
The following cycle parameter: 95°C for 5 min, the 30
cycles of 95°C for 30 s, 57°C for 30 s, 72°C for 30 s,
followed by a final extension of 72°C for 7 min.Statistical analyses
Promoter methylation of NDRG1 was analyzed using
Chi-squared test by SPSS 13.0. The corelation of the
clinicopathological data using unconditional logistic re-
gression was used to estimate odds ratios (ORs) and 95%
confidence intervals (CIs). All models were adjusted for
age at diagnosis. Differences were considered statistically
significant at P < 0.05.Results
NDRG1 mRNA expression in breast tumors
and corresponding normal tissues
Total RNA was extracted and the presence of NDRG1
mRNA was monitored using semiquantitative RT-PCR.
Our results showed that NDRG1 mRNA expression was
not amplified in 45 out of 87 breast tumors, while only
10 normal tissues lost NDRG1 expression in the cor-
responding normal samples. Representative data are
shown in Figure 1. Thus, there was a significant differ-
ence between these two groups (p = 0.000).Figure 1 NDRG1 mRNA expression analysis in breast tumor tissues (T
PCR reaction without DNA. The GAPDH gene was used as internal control.
analyzed using the Peiqing JS-380 Gel Imaging Analysis System after agaro
was derived from formula IA = average absorbance × area, and the NDRG1
way: NDRG1 IA/ GAPDH IA. *P < 0.05.NDRG1 expression in breast tumor MDA-MB-231
and T47D cell lines
RNA and protein were extracted successfully before
and after AZA treatment in MDA-MB-231 and T47D
cell lines, and then was assessed with RT-PCR and
western blotting, respectively. A 175 bp transcript and
43 KD protein corresponding to the NDRG1 gene were
detected in the MDA-MB-231. In contrast, the T47D
cell line displayed a complete absence of the NDRG1
transcript (Figure 2A).
To confirm the epigenetic transcriptional silencing of
NDRG1 in breast cancer, we treated the T47D cell line
with demethylating the agent AZA at 0, 2.5, 5 and 10
μM concentrations, respectively. The result showed that
AZA treatment gradually restored the expression of
NDRG1 in the T47D (Figure 2B).Silencing of NDRG1 associated with the promoter
hypermethylation
Sodium bisulfite sequencing was carried out on 465 bp
fragment with 49 CpG dinucleotides located within
the −379 to +86 island (Figure 3A). The NDRG1-negative
cell line, T47D, showed a hypermethylation of 66% of the
CpG dinucleotides (Figure 3B). In contrast, the cell line
that expressed NDRG1, which was MDA-MB-231, had
lower levels of 16% CpG dinucleotide methylation. The
methylation profile comparing the NDRG1-expression
cell line MDA-MB-231 to the non-expression cell line
T47D demonstrated that the differentially methlylated
dinucleotides were CpGs 15–18, 26–30 and 35–40. The
inactivation of NDRG1 is explained through the high
density of methylation in the T47D cell line (Figure 3B).
This silencing due to hypermethylation was confirmed by) and corresponding adjacent tissues (N). (A) NC represents the
M, Molecular Weight. (B) The PCR products were scanned and
se electrophoresis. The integral absorbance (IA) score for each band
relative expression of each sample was represented in the following
Figure 2 NDRG1 expression analysis using semi-quantitative RT-PCR (A) and western blotting (B) in MDA-MB-231 (MDA) and T47D and
breast cancer cell lines treated with 5-Aza-CdR for 72 h at different concentration. The band A, B, C, D were treated with 0, 2.5, 5,10 μM of
5-Aza-CdR, respectively. NC represents the PCR reaction without DNA (negative control). The GAPDH and β-actin gene were used as a positive
control for RT-PCR and western blotting respectively in this experiment. MW, Molecular Weight.
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in the subsequent expression of NDRG1 (Figure 2). As the
silencing of the NDRG1 gene would be regulated by above
different methylated CpGs , the regions were subsequently
analyzed in primary tumors samples through nested-MSP.
Nested-MSP analysis in breast cancer cell lines
and primary breast tumors
To confirm our bisulfite sequencing results, we then per-
formed nested-MSP in these two breast cancer cell lines
(Figure 4A). The NDRG1 promoter of the T47D cellFigure 3 The methylation status of NDRG1 gene in the fragment from
transcription start site. An fragment of 465 bp (−379 to +86), encompassing
methylation analysis. (B) The bisulfite genomic sequencing of eight individ
cell lines. The forty-nine dinucleotides are numbered in agreement with th
dinucleotides while the gray to blank portion represents the percentage of
according to data of the methylation percentage value. The arrows belowline consistently showed a methylated fragment. The
MDA-MB-231 cell line, which express NDRG1, did not
be affected after AZA treatment (Figure 1). Therefore,
the MSP results of the breast tumor cell lines were
proven with both the data of NDRG1 expression and
sequencing data.
In this study, differentially methylated CpG island re-
gions were subsequently used to analyze the methylation
of the NDRG1 gene in primary breast cancer tumors.
Of the 389 incidence breast cancer cases from a large
number of populations in Qingdao, China, the methylat-−379 to +86. (A) The CpG island of NDRG1 surrounding the
49 CpG dinucleotides with the CpG island was selected for
ual clones was analyze in MDA-MB-231 (MDA) and T47D breast cancer
e sequence. The open circles represent the unmethylated
methylation. On the above side methylation pattern are represented
the CpG dinucleotides represent the MSP primers that were used.
Figure 4 Methylation-specific PCR analysis for NDRG1 methylation in MDA-MB-231 (MDA) and T47D breast cancer cell lines (A), breast
cancer tissues (T) and corresponding normal breast tissues (N) (B). Genomic DNA from breast cancer cell lines and breast tumors treated
with sodium bisulfite were amplified using methylated (M) and unmethylated primers (U). MC was used as a positive control for methylated
reaction, and UC was used as a positive control for unmethylated reaction. NTC was blank control.
Table 2 Correlation of NDRG1 methylation and
its expression
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CpG methylation in the region evaluated by nested-MSP.
Two representative tumor samples are shown in Figure 4B.
For 87 frozen tumor tissues, corresponding normal tissues
from the same patients were obtained as well. Of 87
frozen tumors, 32 were methylated while only thirteen
normal tissues appeared to be methylated. Thus, the
promoter methylation of NDRG1 was observed more
frequently in breast cancer tissues than the corresponding
normal tissues (P = 0.000) (Table 1).
Correlations between NDRG1 promoter methylation
and its expression in breast cancer tissues
In 87 fresh breast cancer tissues, the correlation ana-
lysis revealed that NDRG1 mRNA expression loss was
correlated with its methylation, and the data in Table 2
show that the difference in NDRG1 expression between
methylated and unmethylated tissues was statistically
significant in the samples with tumors and the corre-
sponding normal tissues.
Correlations between NDRG1 promoter methylation
and the clinicopathological data
The clinical significance of the promoter methylation of
the NDRG1 gene was determined by investigating the
relationship between NDRG1 methylation and the cli-
nicopathological characteristics of breast cancer patients,
such as menopause, tumor grade, TNM stage, lymph node
metastasis, p53 mutation, tumor size, HER2 status, andTable 1 Comparison of NDRG1 methylation between
breast tumors and corresponding adjacent tissues
from the same patients (n = 87)
NDRG1 methylation P value
+ -
Tumor tissues 32 55
Adjacent tissues 13 74 0.000the Ki67 proliferation index. Table 3 Shows that the stron-
gest clinicopathological characteristics are for NDRG1
methylation with histology for moderate and poor nuclear
grade status [ORs:1.89 (95%CIs, 1.20-3.20) and ORs: 2.96
(95%CIs, 1.19-7.39), respectively], lymph node invasion
[(ORs: 2.22 (95%CIs, 1.19-4.11)], Metastasis [(ORs: 1.94
(95%CIs, 1.10-3.40)], TNM at stages III/IV [ORs: 2.82
(95%CIs, 1.41-5.62)]. These results suggested that CpG
island methylation in the NDRG1 gene might be an im-
portant prognostic factor for breast cancer.
Discussion
In recent years, NDRG1 has been described as a potential
tumor suppressor gene in various human cancers, includ-
ing breast cancer [3,4,14,15]. In the present study, we first
analyzed the expression of NDRG1 in 87 fresh frozen
breast tumors, corresponding normal tissues and breast
cancer cell lines. The results of the present study showed
that in 87 breast cancer samples, NDRG1 transcripts were
greatly depressed compared with corresponding normal
tissues (p = 0.000). NDRG1 expression was detected in
MDA-MB-231 while it was not present in the T47D cell
line. It is well-known that, during carcinogenesis, a gain of
methylation at the promoters of selected CpG islands and






- 37 18 0.000
Normal tissues
+ 4 9
- 73 1 0.000
Table 3 Clinicopathological features of the 389 patients
with primary breast carcinomas according to methylation
status of NDRG1
Clinical Samples NDRG1
Data n M ORs (95%CIs) P value
Menopausal status
Pre- 162 51 1.0
Post- 227 70 1.86(0.84-4.14) 0.126
Tumor size
<1.0 7 3 1.0
1.0-1.9 136 45 0.84(0.14-4.88) 0.842
2-3 200 61 0.64(0.11-3.69) 0.615
≥3.1 46 12 0.55(0.08-3.59) 0.535
Histological grade
Well 150 35 1.0
Moderate 207 72 1.89(1.20-3.20) 0.017
Poor 32 14 2.96(1.19-7.39) 0.020
Metastasis
Negative 232 63 1.0
Positive 157 58 1.94(1.10-3.40) 0.021
Lymph node invasion
Negative 86 20 1.0
Positive 303 101 2.22(1.19-4.11) 0.011
TNM stage
0/I 87 20 1.0
II 173 53 1.88(0.96-3.67) 0.064
III/IV 129 48 2.82(1.41-5.62) 0.003
p53 mutation
Wild 160 50 1.0
Mutant 229 71 1.04(0.64-1.70) 0.865
HER2 status
Negative 270 86 1.0
Positive 119 35 0.83(0.49-1.39) 0.472
Ki67 proliferation index
<10% 93 32 1.0
10%-32% 152 44 0.66(0.35-1.25) 0.200
≧33% 144 45 0.78(0.41-1.48) 0.441
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was revealed in the existence of CpG islands through the
study of its promoter region. Therefore, treatment with
AZA reversed the methylation status, which was related
to the gradually increased expression of NDRG1 in T47D.
These results indicate that the methylation status of the
NDRG1 gene promoter is an important epigenetic mech-
anism regulating the level of its steady-state expression. In
accordance with the NDRG1-expression of cell line,
MDA-MB-231, and the non-expression of the cell line,T47D, we further investigated the NDRG1 methylation
status of the region from −379 to +86 in the promoter of
these two cell lines. Hypermethylation of NDRG1 was
tested in T47D while the NDRG1 promoter detected the
hypomethylation status in the MDA-MB-231 cell line. We
presume that due to the different methylation statuses of
the NDRG1 promoters in certain regions, the responses of
the NDRG1 promoters in the expression/non-expression
breast cancer cell lines to its expression are different.
Accordingly, the variance in NDRG1 expression between
the methylated and unmethylated tissues was statistically
significant in the breast tumors and corresponding normal
tissues (p = 0.000). Previous research has also demon-
strated that NDRG1 gene reactivation in pancreatic,
gastric, and colon cancer cell lines by the pharmacologic
reversal of DNA methylation occurred via an indirect
mechanism [11-13]. Taken together, all these results indi-
cate that different NDRG1 promoter methylation statuses
are associated with its expression.
Recent emphasis tented to identify the epigenetic change,
especially DNA methylation regulate gene expression
in human carcinogenesis. Kurdistani et al. reported that
gene NDRG1 expression was significantly decreased in
a variety of tumor cell lines and tumor tissue compared
to the normal tissues [5]. The analysis on the structure
of NDRG1 gene found that NDRG1 methylation status
in promoter region could modulate its expression ac-
cording to the CpG island in the first exon [19]. The
NDRG1 gene was epigenetically regulated in pancreatic
[13], colon [15]. The objective of this research was to
study the potential mechanisms involved in silencing of
the NDRG1 gene.
Furthermore, in order to prove that NDRG1 could be
taken as a potential biomarker for breast cancer, the
breast cancer tissues were analyzed further with MSP
assay, and the relationship of the gene methylation sta-
tus with clinicopathological data was determined. In our
current study, the MSP results demonstrated that the
status of methylation had a greater frequency in 87
breast tumors compared with corresponding normal tis-
sues (P < 0.001), which showed that NDRG1 promoter
methylation status was relative to the genetic risk vari-
ants for breast cancer.
Breast cancer is a complex and heterogeneous disease,
the breast pathology includes a mount of entities for
which distinctive histological patterns and different bio-
logical features exist. Patient age, tumor size, lymph in-
vasion, histological grade, hormone receptor status and
HER2 status have been used historically to assess prog-
nosis in women with breast cancer [20]. In our study,
breast tumor samples with histology in moderate and
poor grades, metastasis, TNM at stages III/IV, and
lymph invasion status were found to be more frequent
in methylation than with a high histological grade, no
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sion, which showed that NDRG1 methylation plays an
important role in the course of the histological grade,
metastasis, TNM stages, and lymph invasion status for
breast cancer. It is well-known that histological grade is
based on cell differentiation degree and tumor cell
morphology as a basis for evaluation. Meanwhile, the
NDRG1 gene in various poorly differentiated cancer cells
was a frequent occurrence compared to normal cells
[21-23], and the differentiation stage was viewed as a
crucial standard in the determination of the prognosis
of breast cancer [24]. Accordingly, NDRG1 could take
effect in the process of high lymph node invasion, me-
tastasis and advanced pathological stages [25,26]. Based
on the current findings about the correlation between
the NDRG1 gene, differentiation stages, metastasis and
lymph node invasion, we consider that NDRG1 is a newly
identified differentiation-related and metastasis suppressor
gene in breast cancer, and its methylation is associated
with cell differentiation in the process of provoking cell
tumorigenesis.
Conclusion
In summary, this study provides new evidence that aber-
rant methylation and NDRG1 is involved in the tumori-
genesis of breast cancer, and it could be reactivated
from a silenced state by methylation. It is proposed that
NDRG1 promoter demethylation and the restoration of
NDRG1 expression has potential therapeutic use for
breast cancer. Our findings also provide evidence that
NDRG1 methylation is correlated with histological
grade, metastasis, TNM stages, and lymph invasion status.
However, because relatively little is known about the in-
terrelation between these parameters, additional research
is required to better understand their etiology. Neverthe-
less, the notion that NDRG1 could be reactivated from
a silenced state by methylation might be a possible me-
chanism for breast cancer.
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